NexPlasmaGen: Finalist of the FemTechBreakfastClub 2026 program | NexPlasmaGen
17385
post-template-default,single,single-post,postid-17385,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

NexPlasmaGen: Finalist of the FemTechBreakfastClub 2026 program

26 Jun NexPlasmaGen: Finalist of the FemTechBreakfastClub 2026 program

Posted at 12:36h in Uncategorized by
0 Likes

Montreal / June 26, 2026

NexPlasmaGen has been selected as part of the FemTechBreakfastClub 2026 program and will be pitching at the Montreal Showcase on July 7th in addition to speaking during a Woman Health panel. I look forward to joining an incredible group of investors and founders building the future of women’s health.

Event link: For Founders | FemTech Breakfast Club

#FemTech #WomensHealth #HealthInnovation #Startup #Montreal

ABOUT FemTechBreakfastClub

The FemTech Breakfast Club (FBC) is Canada’s largest national fundraising and pitch platform dedicated specifically to early-stage innovations in women’s health. It aims to bridge the funding gap in FemTech by connecting promising, women-led startups with venture capital (VC) investors and ecosystem partners. The club focuses on several core components to support founders and investors alike: Fundraising Bootcamp: The club selects top startups to participate in an investor-led, virtual bootcamp; National Pitch Showcases: FBC hosts invite-only pitch competitions and showcases alongside major tech conferences across Canada; and Bridging the Gender Gap: The initiative tackles the biases often faced by women-led and gender-diverse health innovators by putting them in front of VCs who are actively looking to invest in women’s health.

ABOUT NEXPLASMAGEN

NexPlasmaGen converges the emerging field of cold plasma biotechnology towards personalized cancer treatment. We develop high-precision cold plasma systems that destroy cancer cells while sparing the healthy tissue. The first application of NexPlasmaGen is the treatment of breast cancer, followed by skin and lung cancer. Its patented cold plasma medical device has the potential to reduce the rate of cancer recurrence as well as side effects and toxicity of the standard of care for the benefit of patients.

Contact :

Dr. Valérie Léveillé, ing., M.Sc.A., CEO/Founder

Tel. : 1-514-229-9458

Email : valerie.leveille@nexplasmagen.com

Website : https://nexplasmagen.com/

No Comments

Post A Comment